Viewing Study NCT01185795


Ignite Creation Date: 2025-12-24 @ 1:48 PM
Ignite Modification Date: 2025-12-30 @ 3:16 PM
Study NCT ID: NCT01185795
Status: COMPLETED
Last Update Posted: 2012-07-02
First Post: 2010-08-18
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Efficacy of Cardioviva™ Probiotic Yogurt Formulation
Sponsor: Micropharma Limited
Organization:

Study Overview

Official Title: Efficacy of a Microencapsulated Probiotic Yogurt Formulation as a Health Promoting Agent
Status: COMPLETED
Status Verified Date: 2012-06
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Background: Several studies have reported limited or no reduction in serum lipid concentrations in response to probiotic formulations. More recently, probiotics have shown promise in treating metabolic disease, due to improved strain selection and delivery technologies.

Objective: To evaluate the lipid lowering efficacy of a yogurt formulation containing microencapsulated Bile Salt Hydrolase (BSH)-active Lactobacillus reuteri cardioviva, taken twice per day over 6 weeks, in subjects with hypercholesterolemia.

Design: This is a double-blinded, multi-centric, placebo-controlled, randomized, parallel-arm study. The study will last a total of 10 weeks including 2-week wash-out, 2-week run-in, and 6- week treatment period.
Detailed Description: None

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: